Request Sample
Request Methodology
Description
Immunosuppressants Market size was expected valued at USD 61.54 billion in 2021, at a CAGR of 14.2% during the forecast period 2022-2028. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in the organ transplantation, autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others. Moreover, immunosuppressants also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis. Immunodeficiency is the major adverse effect associated with the immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects with the immunosuppressants. Immunosuppressants market is growing at a significant CAGR owing to increase in the prevalence of autoimmune disorders and incidence of organ transplantation. For instance, According to World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was increased about 1.8% from 2013. Furthermore, various pipeline products in the market also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies for increasing their revenue in immunosuppressants market.
Key Developments:
In September 2017, Zydus Cadila received FDA final approval for Mycophenolate Mofetil Immunosuppressant injection
In April 2017, Sanofi received FDA approval for Thymoglobulin immunosuppressant drug used for the prevention of acute kidney transplant rejection.
